Crescent Sterling Ltd. Cuts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Crescent Sterling Ltd. cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 402 shares of the biopharmaceutical company’s stock after selling 15 shares during the quarter. Crescent Sterling Ltd.’s holdings in Regeneron Pharmaceuticals were worth $286,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares during the last quarter. International Assets Investment Management LLC raised its position in Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after buying an additional 879,916 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Regeneron Pharmaceuticals by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after acquiring an additional 11,499 shares during the period. Massachusetts Financial Services Co. MA boosted its holdings in shares of Regeneron Pharmaceuticals by 12.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after acquiring an additional 59,769 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in Regeneron Pharmaceuticals by 0.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock valued at $357,945,000 after buying an additional 2,270 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Leerink Partners restated a “market perform” rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,037.33.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $696.88 on Monday. The company has a market capitalization of $76.58 billion, a P/E ratio of 17.25, a P/E/G ratio of 2.19 and a beta of 0.10. The company’s 50-day simple moving average is $751.44 and its two-hundred day simple moving average is $961.06. Regeneron Pharmaceuticals, Inc. has a one year low of $691.00 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.